Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cure Genetics Co. Limited currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio shows a concentrated prosecution history, as evidenced by the presence of 1 pending office action. This prosecution activity is localized within 1 distinct art unit, which suggests the company is currently targeting a specific technical niche. The concentration in this art unit suggests a specialized filing strategy that prioritizes specific technical improvements. This focus on the assigned art unit creates a consistent prosecution environment for the pending matter.
The company's interactions with the USPTO involve 1 distinct examiner. DIBRINO, MARIANNE serves as the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because this examiner handles the entirety of the company's pending workload, the prosecution strategy is centralized. A centralized prosecution model requires the applicant to be highly attuned to the specific interpretation of prior art and procedural requirements favored by the assigned official.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | DIBRINO, MARIANNE | 70d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §102§112DPOther | Final Rejection | 70d overdue | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial